ArticleCNS neuroscience & therapeutics2026
Tumor Electric Field Therapy Inhibits TGF-β/C1R Signaling Axis-Driven Epithelial-Mesenchymal Transition in Glioblastoma.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tumor Electric Field Therapy Inhibits Epithelial-Mesenchymal Transition, Invasion, and Migration of Glioblastoma by Targeting the c-FOS/CXCL14 Axis.CNS neuroscience & therapeutics · 2026Article
- Tumor Electric Field Therapy Inhibits TGF-β/C1R Signaling Axis-Driven Epithelial-Mesenchymal Transition in Glioblastoma.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is one of the most aggressive and treatment-resistant primary brain tumors, with the mesenchymal subtype exhibiting particularly poor prognosis. Tumor electric field therapy (TEFT) has emerged as a promising adjunctive treatment, but its underlying molecular mechanisms remain incompletely understood.
methodsGBM functional states were analyzed using CancerSEA datasets. GBM cell lines were treated with 200 kHz TEFT at 2.2 V/m for 72 h. C1R was knocked down using siRNA and shRNA. Cell morphology, migration, invasion, proliferation, and signaling pathways were assessed through various assays. Findings were validated in animal models and clinical specimens.
resultsC1R was identified at the intersection of TEFT-downregulated genes, poor prognosis markers, and functional state genes. C1R was significantly upregulated in mesenchymal GBM and strongly correlated with epithelial-mesenchymal transition (EMT). Single-cell RNA sequencing revealed C1R was predominantly expressed in MES-like malignant cells with high EMT signature scores. TEFT treatment induced morphological changes from elongated spindle-shaped to rounded epithelial-like morphology, increased E-cadherin expression, and decreased mesenchymal markers (N-cadherin, Vimentin, YKL-40). Mechanistically, TEFT suppressed the TGF-β/SMAD2/3/STAT3 signaling pathway, downregulating C1R expression. C1R knockdown significantly reduced tumor growth in vivo, while exogenous TGF-β restored C1R expression and reversed the mesenchymal phenotype in a dose- and time-dependent manner.
conclusionTEFT inhibits GBM progression by suppressing the TGF-β/SMAD2/3/STAT3/C1R axis, thereby attenuating EMT and reducing tumor aggressiveness. These findings uncover a novel mechanism of TEFT and identify C1R as a potential biomarker and therapeutic target for GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.